Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Treatment

Principles of Therapy

There is no cure for narcolepsy

  • Its disabling symptoms can be controlled with appropriate & targeted therapy
  • The goal is to produce the fullest possible return of normal function at home, school, work, & socially with minimal side effects

Considerations for Choice of Agent

  • Benefit-to-risk ratio (eg efficacy & adverse effects)
  • Convenience of administration
  • Cost

Effective Agents For Daytime Sleepiness

  • If patient has failed adequate doses of stimulant medications, other sleep disorders may be contributing to sleepiness
  • Patient may benefit from combination of long- & short-acting stimulants


Amphetamine & Amphetamine-like Central Nervous System Stimulants

  • Indirect sympathomimetics that increase monoamine levels within the synaptic cleft by enhancing the release of norepinephrine, dopamine, & serotonin, while blocking their reuptake
  • Effective in managing daytime sleepiness
    • Studies show objective improvement in somnolence in 65-85% of patients
    • Low risk of addiction but the risk is greater in patients who are taking high dosages of stimulants, on long-term therapy, & with an underlying psychiatric disorder
  • Amphetamines are most likely to result in the development of tolerance when used in high doses
  • Methylphenidate is usually considered as 1st-line therapy in patients with severe narcolepsy & in those who fail in Modafinil
    • Improves sleep tendency
    • Similar efficacy with Dextroamphetamine but has a better therapeutic index & lower risk of adverse effects
  • Modafinil
    • Indirectly increases wakefulness through inhibition of GABA release via serotonergic mechanism or indirectly on dopaminergic stimulation
      • Stimulates norepinephrine inhibition of the ventrolateral preoptic nucleus which is responsible for promoting sleep
    • 1st-line medication in the treatment of excessive daytime sleepiness & irresistible episodes of sleep
    • May be the 1st-line agent in newly diagnosed patients with mild-moderate narcolepsy
    • Effects:
      • Improves wakefulness in patients with excessive sleepiness
      • Does not generally normalize sleep, thus, may be less effective than other stimulants
      • Risk/benefit ratio has been established in a number of studies
      • Has low abuse potential & not associated with rebound hypersomnolence
  • Armodafinil is the longer half-life enantiomer of Modafinil that has been assessed for treatment of excessive sleepiness in patients with narcolepsy
    • A study have shown that it improves sleepiness as measured by the maintenance of wakefulness test mean sleep latency, & in the Clinical Global Impression of Change


  • Monoamine oxidase B inhibitor
  • May be an effective treatment for daytime sleepiness & cataplexy
    • Improves narcoleptic symptoms, sleep cycles & polysomnographic measurements
    • Decreases occurrence of cataplexy
    • High doses needed; diet-induced hypertension is a risk at effective doses
    • Potential drug & diet-induced interactions limit its use
      • Avoid tyramine or maintain a diet low in tyramine

Sodium oxybate

  • Action: Inhibits the release of GABA, glutamate, & dopamine
  • Effective for the treatment of excessive daytime sleepiness & cataplexy & improvement in the quality of sleep by preventing nocturnal fragmentation
    • Reduces nocturnal awakenings, increases stage non-REM 3 (delta or slow wave) sleep, decreases light sleep & consolidates REM sleep periods
    • Needs high doses of 6-9 g to reach its therapeutic effect
    • Has moderate risk for abuse
    • Better tolerated because it lacks anticholinergic side effects
  • Treatment of choice for narcolepsy with cataplexy
    • Improvement in cataplexy is much more rapid than effect on daytime sleepiness

Effective Agents For Other Narcoleptic Symptoms

  • Stimulant therapy alone, by decreasing drowsiness, often improves cataplexy
  • Sleep paralysis & hypnagogic hallucinations seldom need treatment

Benzodiazepines & Non-benzodiazepines

  • Triazolam showed improved sleep efficiency & overall sleep quality
  • Eszopiclone & Clonazepam have been used with varying success in the treatment of fragmented nocturnal sleep

Norepinephrine Reuptake Inhibitor

  • Effective for the treatment of cataplexy & excessive daytime sleepiness
  • Recommended drug in patients with resistant cataplexy after failure of Venlafaxine, Fluoxetine, & older serotonin reuptake inhibitors
  • Less effective than Modafinil & Sodium oxybate in teenagers & adults
  • Atomoxetine is a highly specific noradrenergic reuptake inhibitor
  • Viloxazine significantly reduces cataplexy, helps treat hallucinations & has few adverse effects
  • Robexitine exerts anticataplectic effects & improve excessive daytime sleepiness

Selective Norepinephrine/Serotonin Reuptake Inhibitors

  • Effective treatment for cataplexy, sleep paralysis, & hypnagogic/hypnopompic hallucinations
  • Recommended drugs due to their greater efficacy & improved side-effect profile
  • Venlafaxine is the most commonly used drug in this class
    • Potent inhibitor of norepinephrine & serotonin
    • Improves excessive daytime sleepiness & cataplexy
    • Helpful in the treatment of hallucinations
    • Easily obtainable & can be taken during wakefulness
  • Action: Block the presynaptic reuptake of catecholamines, thereby increasing their activity; however, they are more selective for serotonin
  • Effective in decreasing cataplexy & inhibiting nocturnal rapid eye movement sleep
  • Selective serotonin reuptake inhibitors are less effective compared to tricyclic antidepressants
    • However, selective serotonin reuptake inhibitors are safer & better tolerated than other antidepressants
  • Not recommended as 1st-line agents for cataplexy because of the availability & better efficacy of newer medications
  • Fluoxetine is the most commonly used selective serotonin reuptake inhibitors for the treatment of cataplexy
  • Femoxitine, Fluvoxamine, Paroxetine & Zimeldine have also shown efficacy

Tricyclic Antidepressants (TCAs)

  • Action: Block the presynaptic reuptake of catecholamines, thus enhancing their postsynaptic activity
  • Have anticataplectic activity
    • Increase muscle tone & suppress rapid eye movement
    • Effective in treating sleep paralysis & hallucinations
  • Clomipramine is the most efficacious & widely used for cataplexy
    • Has the most REM-suppressing activity because of its greater ability to block serotonin reuptake
  • Imipramine has shown efficacy in decreasing hallucinations
  • Rebound cataplexy phenomenon may occur on abrupt discontinuation of tricyclic antidepressants
    • May lead to status cataplecticus when severe
  • Some studies recommend tricyclic antidepressants as last resort due to adverse effects
Editor's Recommendations
Most Read Articles
21 Feb 2021
The efficacy and safety of the two-bag (TB) system are comparable to those of the one-bag (OB) system in adults with diabetic ketoacidosis (DKA), results of a study have shown. Both approaches can be considered in adult DKA patients.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.